Comparative Pharmacology
Head-to-head clinical analysis: RIFAMPICIN versus RIMACTANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RIFAMPICIN versus RIMACTANE.
Rifampicin vs RIMACTANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA-dependent RNA polymerase by binding to the beta subunit, thereby blocking RNA transcription.
Inhibits DNA-dependent RNA polymerase in susceptible bacteria, blocking RNA transcription.
600 mg orally or intravenously once daily
Rifampin 600 mg orally once daily; intravenous as alternative if oral not possible.
None Documented
None Documented
Terminal elimination half-life is 3-5 hours initially, but decreases to 2-3 hours after repeated dosing due to auto-induction of hepatic enzymes. Clinically significant for daily dosing and need for consistent timing.
Clinical Note
moderateRifampicin + Digoxin
"The metabolism of Digoxin can be increased when combined with Rifampicin."
Clinical Note
moderateRifampicin + Digitoxin
"The metabolism of Digitoxin can be increased when combined with Rifampicin."
Clinical Note
moderateRifampicin + Torasemide
"The metabolism of Torasemide can be increased when combined with Rifampicin."
Clinical Note
moderateRifampicin + Deferasirox
"The serum concentration of Deferasirox can be decreased when it is combined with Rifampicin."
Terminal elimination half-life is 3-5 hours in adults with normal hepatic function; prolonged to 5-10 hours in hepatic impairment or obstructive jaundice. Autoinduction of metabolism reduces half-life by 20-40% after repeated dosing.
Primarily hepatic (biliary) excretion into feces; about 60-65% as unchanged drug and metabolites. Renal elimination accounts for approximately 30% (mostly as metabolites). <5% excreted unchanged in urine.
Primarily hepatic metabolism to deacetylated metabolite; ~60-65% of dose excreted in feces (biliary), ~15-30% in urine (unchanged and metabolites). Up to 10% via lacrimal, sweat, saliva, and other routes.
Category C
Category C
Rifamycin Antibiotic
Rifamycin Antibiotic